MCID: STR020
MIFTS: 55

Strabismus

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Strabismus

MalaCards integrated aliases for Strabismus:

Name: Strabismus 56 12 74 54 6 15 71
Strabismus, Susceptibility to, 1 56 13
Strabismus, Susceptibility to 56
Susceptibility to Strabismus 29
Strabismus 1 56

Characteristics:

OMIM:

56
Inheritance:
familial, but no simple mendelian inheritance established


Classifications:



External Ids:

Disease Ontology 12 DOID:540
OMIM 56 185100
ICD9CM 34 378.7
ICD10 32 H50.8 H50.9
MedGen 41 C1861449
UMLS 71 C0029831 C0038379

Summaries for Strabismus

OMIM : 56 Strabismus, a misalignment of the eyes also referred to as 'squint,' is one of the most common ocular disorders in humans, affecting 1 to 4% of the population. It is frequently associated with amblyopia (uniocular visual neglect) (Parikh et al., 2003). Strabismus is also a feature of several syndromes, including congenital fibrosis of extraocular muscles (see, e.g., CFEOM1; 135700), Duane retraction syndrome (126800), and chronic progressive external ophthalmoplegia with myopathy (530000). (185100)

MalaCards based summary : Strabismus, also known as strabismus, susceptibility to, 1, is related to pathologic nystagmus and myelomeningocele, and has symptoms including ophthalmoplegia, spasm of conjugate gaze and anomalies of divergence. An important gene associated with Strabismus is TYR (Tyrosinase). The drugs Dexmedetomidine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are microtropia and Decreased NANOG protein expression

Wikipedia : 74 Strabismus is a condition in which the eyes do not properly align with each other when looking at an... more...

Related Diseases for Strabismus

Diseases in the Strabismus family:

Rare Disorder with Strabismus

Diseases related to Strabismus via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 672, show less)
# Related Disease Score Top Affiliating Genes
1 pathologic nystagmus 32.4 TYR KIF7 GNB1 GALC
2 myelomeningocele 31.5 VANGL2 VANGL1 SLC2A1
3 alacrima, achalasia, and mental retardation syndrome 31.3 STXBP1 SLC2A1 MPP4 MED13L GNB1 DHX30
4 microcephaly 30.9 STXBP1 SPART SLC2A1 POGZ FOXG1 DHX30
5 anencephaly 30.8 VANGL2 VANGL1 KIF7
6 autism 30.6 TMCO1 STXBP1 POGZ PCDH19 FOXG1 DHX30
7 mechanical strabismus 12.7
8 mental retardation, anterior maxillary protrusion, and strabismus 12.6
9 hemifacial hyperplasia with strabismus 12.5
10 ptosis, strabismus, and ectopic pupils 12.5
11 speech development, delayed, with facial asymmetry, strabismus, and transverse earlobe crease 12.3
12 exotropia 12.2
13 paralytic squint 12.2
14 esotropia 12.2
15 syndromic disorder with strabismus 12.2
16 severe intellectual disability-hypotonia-strabismus-coarse face-planovalgus syndrome 12.1
17 rare genetic disorder with strabismus 12.1
18 syndromic genetic disorder with strabismus 12.1
19 rare disorder with strabismus 12.1
20 craniostenosis with strabismus 12.1
21 mehes syndrome 11.9
22 mental retardation, autosomal recessive 36 11.7
23 tukel syndrome 11.6
24 hypertropia 11.6
25 white-sutton syndrome 11.6
26 amblyopia 11.6
27 fourth cranial nerve palsy, familial congenital 11.6
28 abducens nerve disease 11.6
29 duane retraction syndrome 11.5
30 crouzon syndrome 11.5
31 retinoblastoma 11.5
32 farsightedness 11.4
33 fibrosis of extraocular muscles, congenital, 2 11.4
34 3mc syndrome 11.4
35 mcpherson robertson cammarano syndrome 11.4
36 microdontia hypodontia short stature 11.4
37 singh chhaparwal dhanda syndrome 11.4
38 brown syndrome 11.4
39 retinoschisis 1, x-linked, juvenile 11.4
40 ocular albinism 11.4
41 hypotropia 11.4
42 duane retraction syndrome 1 11.3
43 ocular motility disease 11.3
44 3-methylglutaconic aciduria, type iii 11.3
45 cyclotropia 11.3
46 krauss herman holmes syndrome 11.3
47 fibrosis of extraocular muscles, congenital, 1 11.3
48 moebius syndrome 11.3
49 coloboma of macula 11.2
50 apert syndrome 11.2
51 congenital toxoplasmosis 11.2
52 coats disease 11.2
53 oculocutaneous albinism 11.2
54 saethre-chotzen syndrome 11.2
55 blepharophimosis, ptosis, and epicanthus inversus 11.2
56 kabuki syndrome 1 11.2
57 neurodegeneration with brain iron accumulation 2a 11.2
58 peters-plus syndrome 11.2
59 duane retraction syndrome 2 11.2
60 persistent hyperplastic primary vitreous 11.2
61 fetal thalidomide syndrome 11.2
62 arthrogryposis, distal, type 5 11.1
63 cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 11.1
64 corneal dystrophy, congenital stromal 11.1
65 cortical dysplasia, complex, with other brain malformations 1 11.1
66 naegeli-franceschetti-jadassohn syndrome 11.1
67 mental retardation, autosomal dominant 18 11.1
68 hypotonia, infantile, with psychomotor retardation 11.1
69 mental retardation, autosomal recessive 55 11.1
70 gatad2b-associated neurodevelopmental disorder 11.1
71 monocular esotropia 11.1
72 suppression amblyopia 11.1
73 alternating exotropia 11.1
74 albinism, oculocutaneous, type vi 11.0
75 kaufman oculocerebrofacial syndrome 11.0
76 marinesco-sjogren syndrome 11.0
77 orofaciodigital syndrome ix 11.0
78 nystagmus 6, congenital, x-linked 11.0
79 craniofrontonasal syndrome 11.0
80 nystagmus 1, congenital, x-linked 11.0
81 desmosterolosis 11.0
82 albinism, oculocutaneous, type ib 11.0
83 bestrophinopathy, autosomal recessive 11.0
84 nephrotic syndrome, type 5, with or without ocular abnormalities 11.0
85 congenital disorder of glycosylation, type iu 11.0
86 intellectual developmental disorder with persistence of fetal hemoglobin 11.0
87 jansen-de vries syndrome 11.0
88 rahman syndrome 11.0
89 catifa syndrome 11.0
90 exudative vitreoretinopathy 11.0
91 x-linked congenital stationary night blindness 11.0
92 ophn1 syndrome 11.0
93 kearns-sayre syndrome 11.0
94 adenylosuccinase deficiency 10.9
95 stickler syndrome, type i 10.9
96 brachydactyly-nystagmus-cerebellar ataxia 10.9
97 central core disease of muscle 10.9
98 myhre syndrome 10.9
99 jacobsen syndrome 10.9
100 marcus gunn phenomenon 10.9
101 skin creases, congenital symmetric circumferential, 1 10.9
102 nystagmus 2, congenital, autosomal dominant 10.9
103 hemifacial microsomia 10.9
104 char syndrome 10.9
105 radial ray hypoplasia with choanal atresia 10.9
106 robinow-sorauf syndrome 10.9
107 nystagmus 4, congenital, autosomal dominant 10.9
108 arthrogryposis, distal, type 2a 10.9
109 abetalipoproteinemia 10.9
110 albinism, oculocutaneous, type ia 10.9
111 albinism, oculocutaneous, type ii 10.9
112 albinism, oculocutaneous, type iii 10.9
113 congenital disorder of glycosylation, type ia 10.9
114 sengers syndrome 10.9
115 cerebellar hypoplasia with endosteal sclerosis 10.9
116 gapo syndrome 10.9
117 glutathionuria 10.9
118 mcdonough syndrome 10.9
119 mucolipidosis iv 10.9
120 cousin syndrome 10.9
121 peroxisomal acyl-coa oxidase deficiency 10.9
122 subaortic stenosis--short stature syndrome 10.9
123 hypomelanosis of ito 10.9
124 mental retardation, x-linked, with cerebellar hypoplasia and distinctive facial appearance 10.9
125 albinism, ocular, type i 10.9
126 nystagmus 5, congenital, x-linked 10.9
127 mental retardation, x-linked 101 10.9
128 congenital disorder of glycosylation, type iy 10.9
129 linear skin defects with multiple congenital anomalies 3 10.9
130 anemia, sideroblastic, and spinocerebellar ataxia 10.9
131 focal dermal hypoplasia 10.9
132 night blindness, congenital stationary, type 1a 10.9
133 waisman syndrome 10.9
134 fibrosis of extraocular muscles, congenital, 3a, with or without extraocular involvement 10.9
135 neurofibromatosis-noonan syndrome 10.9
136 cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss 10.9
137 ehlers-danlos syndrome, musculocontractural type, 1 10.9
138 stickler syndrome, type ii 10.9
139 bohring-opitz syndrome 10.9
140 phelan-mcdermid syndrome 10.9
141 hemifacial myohyperplasia 10.9
142 polymicrogyria, bilateral frontoparietal 10.9
143 spastic paraplegia 7, autosomal recessive 10.9
144 nystagmus 3, congenital, autosomal dominant 10.9
145 chromosome 15q11-q13 duplication syndrome 10.9
146 congenital disorder of glycosylation, type ie 10.9
147 pitt-hopkins syndrome 10.9
148 crouzon syndrome with acanthosis nigricans 10.9
149 spastic paraplegia 35, autosomal recessive 10.9
150 spastic paraplegia 50, autosomal recessive 10.9
151 congenital disorder of glycosylation, type ip 10.9
152 stickler syndrome, type iv 10.9
153 pitt-hopkins-like syndrome 2 10.9
154 congenital disorder of glycosylation, type ir 10.9
155 infantile cerebellar-retinal degeneration 10.9
156 facial paresis, hereditary congenital, 3 10.9
157 nystagmus 7, congenital, autosomal dominant 10.9
158 neurodevelopmental disorder with spastic diplegia and visual defects 10.9
159 periventricular nodular heterotopia 6 10.9
160 xia-gibbs syndrome 10.9
161 helsmoortel-van der aa syndrome 10.9
162 poretti-boltshauser syndrome 10.9
163 yuan-harel-lupski syndrome 10.9
164 corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia 10.9
165 hao-fountain syndrome 10.9
166 mental retardation, autosomal dominant 42 10.9
167 congenital heart defects, dysmorphic facial features, and intellectual developmental disorder 10.9
168 neurodevelopmental disorder with severe motor impairment and absent language 10.9
169 liang-wang syndrome 10.9
170 congenital methemoglobinemia 10.9
171 loeys-dietz syndrome 10.9
172 congenital stationary night blindness 10.9
173 chromosome 15q24 deletion syndrome 10.9
174 multiple congenital anomalies-hypotonia-seizures syndrome 10.9
175 complex cortical dysplasia with other brain malformations 10.9
176 diamond-blackfan anemia 10.9
177 ocular albinism, x-linked 10.9
178 unc80 deficiency 10.9
179 8q12 microduplication syndrome 10.9
180 autosomal dominant intellectual disability 49 10.9
181 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 10.9
182 hereditary congenital facial paresis 10.9
183 hivep2-related intellectual disability 10.9
184 infantile choroidocerebral calcification syndrome 10.9
185 iqsec2 10.9
186 maternal hyperphenylalaninemia 10.9
187 metaphyseal dysostosis-intellectual disability-conductive deafness syndrome 10.9
188 n-acetyl-alpha-d-galactosaminidase deficiency type iii 10.9
189 progeroid syndrome petty type 10.9
190 tetrasomy 9p 10.9
191 x-linked intellectual disability, najm type 10.9
192 10q26 deletion syndrome 10.9
193 19p13.13 deletion syndrome 10.9
194 alg1-congenital disorder of glycosylation 10.9
195 alg6-congenital disorder of glycosylation 10.9
196 cask-related intellectual disability 10.9
197 autosomal recessive congenital stationary night blindness 10.9
198 phakomatosis pigmentokeratotica 10.9
199 visual epilepsy 10.9 STXBP1 SLC2A1 POGZ NALCN MPP4 GNB1
200 total spina bifida aperta 10.8 VANGL2 VANGL1
201 cervicothoracic spina bifida aperta 10.8 VANGL2 VANGL1
202 cervical spina bifida aperta 10.8 VANGL2 VANGL1
203 lumbosacral spina bifida aperta 10.8 VANGL2 VANGL1
204 thoracolumbosacral spina bifida aperta 10.8 VANGL2 VANGL1
205 upper thoracic spina bifida aperta 10.8 VANGL2 VANGL1
206 total spina bifida cystica 10.8 VANGL2 VANGL1
207 thoracolumbosacral spina bifida cystica 10.8 VANGL2 VANGL1
208 lumbosacral spina bifida cystica 10.8 VANGL2 VANGL1
209 refractive error 10.8
210 cervical spina bifida cystica 10.8 VANGL2 VANGL1
211 west syndrome 10.8 STXBP1 SLC2A1 PCDH19 GNB1 FOXG1
212 cervicothoracic spina bifida cystica 10.8 VANGL2 VANGL1
213 upper thoracic spina bifida cystica 10.8 VANGL2 VANGL1
214 lennox-gastaut syndrome 10.8 STXBP1 SLC2A1 PCDH19 FOXG1 ADGRG1
215 infancy electroclinical syndrome 10.8 STXBP1 PCDH19 FOXG1
216 epileptic encephalopathy, early infantile, 6 10.8 STXBP1 SLC2A1 PCDH19 FOXG1
217 electroclinical syndrome 10.8 STXBP1 SLC2A1 PCDH19
218 childhood electroclinical syndrome 10.8 STXBP1 SLC2A1 PCDH19
219 congenital trochlear nerve palsy 10.8
220 autosomal dominant non-syndromic intellectual disability 10.8 STXBP1 POGZ MED13L FOXG1
221 syndromic intellectual disability 10.7 STXBP1 POGZ MED13L
222 physical disorder 10.7 VANGL2 VANGL1 FOXG1
223 benign familial infantile epilepsy 10.7 STXBP1 SLC2A1 PCDH19
224 anisometropia 10.7
225 joint laxity, short stature, and myopia 10.7
226 myopia 10.7
227 spasticity 10.7 STXBP1 SLC2A1 KIF7
228 chronic progressive external ophthalmoplegia 10.7
229 pervasive developmental disorder 10.7 STXBP1 POGZ PCDH19 FOXG1
230 paroxysmal choreoathetosis 10.7 SLC2A1 PCDH19
231 early infantile epileptic encephalopathy 10.7 STXBP1 SLC2A1 PCDH19 FOXG1
232 tolosa-hunt syndrome 10.7
233 deafness, autosomal recessive 62 10.7 VANGL2 FOXG1
234 aceruloplasminemia 10.7 SPART SLC2A1 KIF7
235 astigmatism 10.7
236 epilepsy, myoclonic juvenile 10.7 STXBP1 SLC2A1 PCDH19
237 brachydactyly, type b1 10.7 VANGL2 VANGL1
238 ptosis 10.7
239 cataract 10.6
240 spina bifida occulta 10.6 VANGL2 VANGL1
241 landau-kleffner syndrome 10.6 STXBP1 PCDH19
242 fourth cranial nerve palsy 10.6
243 horizontal gaze palsy with progressive scoliosis 10.6
244 aicardi syndrome 10.6 PCDH19 ADGRG1
245 eye disease 10.6
246 retinal detachment 10.6
247 oculomotor nerve paralysis 10.6
248 benign familial neonatal epilepsy 10.6 STXBP1 PCDH19
249 accommodative esotropia 10.5
250 epileptic encephalopathy, early infantile, 9 10.5 STXBP1 PCDH19
251 endophthalmitis 10.5
252 benign epilepsy with centrotemporal spikes 10.5 STXBP1 SLC2A1 PCDH19
253 ocular dominance 10.5
254 exudative vitreoretinopathy 1 10.4
255 cellulitis 10.4
256 childhood absence epilepsy 10.4 STXBP1 SLC2A1 PCDH19
257 cerebral palsy 10.4
258 torticollis 10.4
259 exophthalmos 10.4
260 cranial nerve palsy 10.4
261 myopathy 10.3
262 orbital cellulitis 10.3
263 scotoma 10.3
264 down syndrome 10.3
265 cycloplegia 10.3
266 brown's tendon sheath syndrome 10.3
267 scleritis 10.3
268 craniosynostosis 10.3
269 myasthenia gravis 10.3
270 intraocular pressure quantitative trait locus 10.3
271 hydrocephalus 10.3
272 graves' disease 10.3
273 epilepsy, idiopathic generalized 10.2 STXBP1 SLC2A1 PCDH19
274 polykaryocytosis inducer 10.2
275 yemenite deaf-blind hypopigmentation syndrome 10.2
276 pain agnosia 10.2
277 congenital ptosis 10.2
278 abnormal retinal correspondence 10.2
279 familial retinoblastoma 10.2
280 congenital nystagmus 10.2
281 myositis 10.2
282 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
283 subacute delirium 10.2
284 isolated duane retraction syndrome 10.2
285 hypertelorism 10.2
286 synostosis 10.2
287 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 1 10.1
288 trochlear nerve disease 10.1
289 intermittent squint 10.1
290 autosomal dominant progressive external ophthalmoplegia 10.1
291 mitochondrial dna-related progressive external ophthalmoplegia 10.1
292 aniseikonia 10.1
293 ischemia 10.1
294 dyslexia 10.1
295 blepharospasm 10.1
296 monofixation syndrome 10.1
297 plagiocephaly 10.1
298 hand skill, relative 10.1
299 neural tube defects 10.1
300 neuroretinitis 10.1
301 blind hypotensive eye 10.1
302 optic nerve disease 10.1
303 retinitis 10.1
304 movement disease 10.1
305 47,xyy 10.1
306 keratitis, hereditary 10.1
307 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 10.1
308 retinitis pigmentosa 10.1
309 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 2 10.1
310 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 4 10.1
311 microvascular complications of diabetes 5 10.1
312 scoliosis 10.1
313 blepharophimosis 10.1
314 leukocoria 10.1
315 malignant hyperthermia 10.1
316 learning disability 10.1
317 toxoplasmosis 10.1
318 48,xyyy 10.1
319 hypotonia 10.1
320 abducens palsy 10.0
321 optic nerve hypoplasia, bilateral 10.0
322 schizophrenia 10.0
323 ataxia and polyneuropathy, adult-onset 10.0
324 macular degeneration, age-related, 1 10.0
325 stuttering 10.0
326 ametropic amblyopia 10.0
327 hypopyon 10.0
328 enophthalmos 10.0
329 social phobia 10.0
330 presbyopia 10.0
331 periventricular leukomalacia 10.0
332 uveitis 10.0
333 dysostosis 10.0
334 keratopathy 10.0
335 internuclear ophthalmoplegia 10.0
336 neuropathy 10.0
337 senile cataract 10.0
338 albinism 10.0
339 glioma 10.0
340 posttransplant acute limbic encephalitis 10.0
341 glial tumor 10.0
342 marfan syndrome 10.0
343 williams-beuren syndrome 10.0
344 cryptorchidism, unilateral or bilateral 10.0
345 phenylketonuria 10.0
346 pars planitis 10.0
347 melanoma, cutaneous malignant 10 10.0
348 cytomegalovirus retinitis 10.0
349 keratoconus 10.0
350 disuse amblyopia 10.0
351 corneal edema 10.0
352 chorioretinal scar 10.0
353 vascular disease 10.0
354 melanoma 10.0
355 retinal vascular disease 10.0
356 congenital myasthenic syndrome 10.0
357 craniopharyngioma 10.0
358 neuromuscular disease 10.0
359 conjunctivitis 10.0
360 muscular atrophy 10.0
361 corneal ulcer 10.0
362 influenza 10.0
363 neurofibromatosis 10.0
364 amyloidosis 10.0
365 intracranial hypertension 10.0
366 alternating esotropia 10.0
367 chromosomal triplication 10.0
368 ocular neuromyotonia 10.0
369 pyogenic granuloma 10.0
370 syndromic craniosynostosis 10.0
371 spasmus nutans 10.0
372 cerebral visual impairment 10.0
373 angelman syndrome 9.9
374 autoimmune disease 9.9
375 machado-joseph disease 9.9
376 multiple sclerosis 9.9
377 epicanthus 9.9
378 epidermoid cysts 9.9
379 attention deficit-hyperactivity disorder 9.9
380 motion sickness 9.9
381 prader-willi syndrome 9.9
382 supravalvular aortic stenosis 9.9
383 telecanthus 9.9
384 joubert syndrome 1 9.9
385 persistent hyperplastic primary vitreous, autosomal recessive 9.9
386 intracranial hypertension, idiopathic 9.9
387 nonarteritic anterior ischemic optic neuropathy 9.9
388 anxiety 9.9
389 leukemia, acute lymphoblastic 3 9.9
390 cardiac conduction disease with or without dilated cardiomyopathy 9.9
391 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
392 alkuraya-kucinskas syndrome 9.9
393 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.9
394 usher syndrome 9.9
395 autosomal recessive disease 9.9
396 cone dystrophy 9.9
397 inguinal hernia 9.9
398 myoglobinuria 9.9
399 isolated ectopia lentis 9.9
400 hypospadias 9.9
401 lens subluxation 9.9
402 lyme disease 9.9
403 monocular exotropia 9.9
404 retinal perforation 9.9
405 branch retinal artery occlusion 9.9
406 central retinal artery occlusion 9.9
407 vestibular nystagmus 9.9
408 autosomal dominant cerebellar ataxia 9.9
409 epilepsy 9.9
410 myotonia congenita 9.9
411 ectodermal dysplasia 9.9
412 systemic scleroderma 9.9
413 filamentary keratitis 9.9
414 mitochondrial myopathy 9.9
415 situs inversus 9.9
416 placenta disease 9.9
417 retinal artery occlusion 9.9
418 rubella 9.9
419 chorioretinitis 9.9
420 keratoconjunctivitis 9.9
421 orbital plasma cell granuloma 9.9
422 meningitis 9.9
423 dextrocardia 9.9
424 alopecia 9.9
425 muscular dystrophy 9.9
426 myotonic dystrophy 9.9
427 dwarfism 9.9
428 linear scleroderma 9.9
429 optic pathway glioma 9.9
430 headache 9.9
431 myotonia 9.9
432 tremor 9.9
433 congenital amyoplasia 9.9
434 neurofibromatosis, type ii 9.7
435 pfeiffer syndrome 9.7
436 acroosteolysis 9.7
437 basal cell nevus syndrome 9.7
438 brachydactyly, type c 9.7
439 breast cancer 9.7
440 sotos syndrome 1 9.7
441 cleft palate, isolated 9.7
442 seizures, benign familial neonatal, 1 9.7
443 distichiasis 9.7
444 hemifacial hyperplasia 9.7
445 facial spasm 9.7
446 hashimoto thyroiditis 9.7
447 hemifacial atrophy, progressive 9.7
448 hemifacial spasm, familial 9.7
449 huntington disease 9.7
450 hypercholesterolemia, familial, 1 9.7
451 hyperostosis frontalis interna 9.7
452 multiple system atrophy 1 9.7
453 lacrimal duct defect 9.7
454 leukemia, chronic lymphocytic 9.7
455 melanoma, uveal 9.7
456 migraine with or without aura 1 9.7
457 myotonic dystrophy 1 9.7
458 night blindness, congenital stationary, autosomal dominant 2 9.7
459 optic atrophy 1 9.7
460 poland syndrome 9.7
461 dowling-degos disease 1 9.7
462 spinal arachnoiditis 9.7
463 sturge-weber syndrome 9.7
464 symphalangism, proximal, 1a 9.7
465 chromosome 2q35 duplication syndrome 9.7
466 tarsal coalition 9.7
467 tritanopia 9.7
468 uvula, bifid 9.7
469 argininemia 9.7
470 constricting bands, congenital 9.7
471 donnai-barrow syndrome 9.7
472 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 9.7
473 hydrocephalus, congenital, 1 9.7
474 familial mediterranean fever 9.7
475 galactosialidosis 9.7
476 ocular motor apraxia 9.7
477 gyrate atrophy of choroid and retina 9.7
478 pancreatic cancer 9.7
479 3mc syndrome 2 9.7
480 colorblindness, partial, deutan series 9.7
481 nanophthalmos 1 9.7
482 cataract 24 9.7
483 stroke, ischemic 9.7
484 leukemia, acute myeloid 9.7
485 branchiootic syndrome 1 9.7
486 polydactyly 9.7
487 alveolar soft part sarcoma 9.7
488 gaze palsy, familial horizontal, with progressive scoliosis 1 9.7
489 duane-radial ray syndrome 9.7
490 muscular dystrophy, congenital, lmna-related 9.7
491 muscle hypertrophy 9.7
492 carbonic anhydrase va deficiency, hyperammonemia due to 9.7
493 cataract 45 9.7
494 chorea, childhood-onset, with psychomotor retardation 9.7
495 pulmonary hypertension 9.7
496 aspiration pneumonia 9.7
497 lambert-eaton myasthenic syndrome 9.7
498 congenital hypothyroidism 9.7
499 foodborne botulism 9.7
500 periventricular nodular heterotopia 9.7
501 brachydactyly 9.7
502 tooth agenesis 9.7
503 primary congenital glaucoma 9.7
504 distal arthrogryposis 9.7
505 spastic cerebral palsy 9.7
506 brachyolmia 9.7
507 metabolic acidosis 9.7
508 arteritic anterior ischemic optic neuropathy 9.7
509 autism spectrum disorder 9.7
510 apraxia 9.7
511 porencephaly 9.7
512 autosomal recessive non-syndromic intellectual disability 9.7
513 cardiac arrest 9.7
514 omphalocele 9.7
515 anterior segment dysgenesis 9.7
516 thrombosis 9.7
517 autosomal dominant non-syndromic intellectual disability 1 9.7
518 hereditary lymphedema i 9.7
519 muscular disease 9.7
520 chromosomal disease 9.7
521 covid-19 9.7
522 benign teratoma 9.7
523 nanophthalmos 9.7
524 sensorineural hearing loss 9.7
525 cysticercosis 9.7
526 xerophthalmia 9.7
527 dry eye syndrome 9.7
528 pre-eclampsia 9.7
529 rickets 9.7
530 partial third-nerve palsy 9.7
531 intracranial aneurysm 9.7
532 spastic diplegia 9.7
533 hemiplegia 9.7
534 brucellosis 9.7
535 aqueous misdirection 9.7
536 sarcoma 9.7
537 hypoparathyroidism 9.7
538 arteriovenous malformation 9.7
539 accommodative spasm 9.7
540 clubfoot 9.7
541 arachnoiditis 9.7
542 paranoid schizophrenia 9.7
543 entropion 9.7
544 leukemia 9.7
545 leiomyoma 9.7
546 quadriplegia 9.7
547 choreatic disease 9.7
548 keratoconjunctivitis sicca 9.7
549 shipyard eye 9.7
550 gout 9.7
551 tuberous sclerosis 9.7
552 eclampsia 9.7
553 panophthalmitis 9.7
554 multiple cranial nerve palsy 9.7
555 sick sinus syndrome 9.7
556 visual pathway disease 9.7
557 facial paralysis 9.7
558 iritis 9.7
559 orbital cyst 9.7
560 hypothyroidism 9.7
561 papilledema 9.7
562 olivopontocerebellar atrophy 9.7
563 disease of mental health 9.7
564 candidiasis 9.7
565 ectropion 9.7
566 ventricular septal defect 9.7
567 ocular melanoma 9.7
568 facial hemiatrophy 9.7
569 hyperostosis 9.7
570 constipation 9.7
571 factor xiii deficiency 9.7
572 transient cerebral ischemia 9.7
573 pharyngitis 9.7
574 neuroaxonal dystrophy 9.7
575 acromegaly 9.7
576 basal cell carcinoma 9.7
577 hemangioma 9.7
578 cystic teratoma 9.7
579 glioblastoma multiforme 9.7
580 neurilemmoma 9.7
581 mood disorder 9.7
582 brain stem glioma 9.7
583 spindle cell sarcoma 9.7
584 pustulosis of palm and sole 9.7
585 macular retinal edema 9.7
586 rhinitis 9.7
587 myotonic disease 9.7
588 hypotrichosis 9.7
589 intraocular retinoblastoma 9.7
590 intracranial hypotension 9.7
591 poliomyelitis 9.7
592 optic nerve glioma 9.7
593 adjustment disorder 9.7
594 dystonia 9.7
595 mature teratoma 9.7
596 volkmann contracture 9.7
597 third cranial nerve disease 9.7
598 retinal disease 9.7
599 hemoglobinuria 9.7
600 lymphopenia 9.7
601 acquired immunodeficiency syndrome 9.7
602 compartment syndrome 9.7
603 mitochondrial metabolism disease 9.7
604 thyroiditis 9.7
605 childhood leukemia 9.7
606 hyperthyroidism 9.7
607 osteochondrosis 9.7
608 chronic rhinitis 9.7
609 osteochondritis dissecans 9.7
610 retinal degeneration 9.7
611 night blindness 9.7
612 herpes zoster 9.7
613 myeloid leukemia 9.7
614 psoriasis 9.7
615 skin melanoma 9.7
616 gas gangrene 9.7
617 waardenburg's syndrome 9.7
618 ocular hypertension 9.7
619 orbital disease 9.7
620 iridocyclitis 9.7
621 blepharitis 9.7
622 encephalitis 9.7
623 toxocariasis 9.7
624 developmental coordination disorder 9.7
625 hypereosinophilic syndrome 9.7
626 mitochondrial disorders 9.7
627 athetosis 9.7
628 bronchopulmonary dysplasia 9.7
629 carcinoma showing thymus-like differentiation 9.7
630 cataract-glaucoma 9.7
631 charlie m syndrome 9.7
632 chiari malformation 9.7
633 congenital hydrocephalus 9.7
634 congenital rubella 9.7
635 congenital zika syndrome 9.7
636 craniorachischisis 9.7
637 diaphragmatic hernia exomphalos corpus callosum agenesis 9.7
638 double discordia 9.7
639 familial sick sinus syndrome 9.7
640 haemophilus influenzae 9.7
641 herpes zoster ophthalmicus 9.7
642 ligneous conjunctivitis 9.7
643 neonatal stroke 9.7
644 ocular toxoplasmosis 9.7
645 sinonasal undifferentiated carcinoma 9.7
646 soft tissue sarcoma 9.7
647 streptococcal group a invasive disease 9.7
648 tuberculous meningitis 9.7
649 weber syndrome 9.7
650 aneurysm 9.7
651 cerebral aneurysms 9.7
652 developmental dyspraxia 9.7
653 head injury 9.7
654 hemifacial spasm 9.7
655 pituitary tumors 9.7
656 thomsen's myotonia 9.7
657 systemic autoimmune disease 9.7
658 nasal glial heterotopia 9.7
659 partial deletion of the short arm of chromosome 8 9.7
660 euthyroid graves orbitopathy 9.7
661 juvenile myasthenia gravis 9.7
662 spontaneous intracranial hypotension 9.7
663 rhombencephalosynapsis 9.7
664 pik3ca-related overgrowth syndrome 9.7
665 focal myositis 9.7
666 peripapillary staphyloma 9.7
667 rare tumor 9.7
668 overgrowth syndrome 9.7
669 epiblepharon 9.7
670 presynaptic congenital myasthenic syndromes 9.7
671 oculomotor apraxia 9.7
672 polyendocrinopathy 9.7

Graphical network of the top 20 diseases related to Strabismus:



Diseases related to Strabismus

Symptoms & Phenotypes for Strabismus

Human phenotypes related to Strabismus:

31 (showing 1, show less)
# Description HPO Frequency HPO Source Accession
1 microtropia 31 HP:0031724

Symptoms via clinical synopsis from OMIM:

56
Eyes:
strabismus
microtropia
cyclic strabismus (periodic esotrophia)

Clinical features from OMIM:

185100

UMLS symptoms related to Strabismus:


ophthalmoplegia, spasm of conjugate gaze, anomalies of divergence

GenomeRNAi Phenotypes related to Strabismus according to GeneCards Suite gene sharing:

26 (showing 2, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased NANOG protein expression GR00184-A-3 9.02 KIF7 MED13L
2 Decreased NANOG protein expression GR00184-A-6 9.02 KIF7 MED13L NALCN

MGI Mouse Phenotypes related to Strabismus:

45 (showing 7, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ADGRG1 FOXG1 GALC GNB1 NALCN PCDH19
2 cellular MP:0005384 10.11 ADGRG1 FOXG1 GALC GNB1 KIF7 MPP4
3 growth/size/body region MP:0005378 10 DHX30 FOXG1 GALC GNB1 KIF7 POGZ
4 mortality/aging MP:0010768 10 DHX30 FOXG1 GALC GNB1 KIF7 NALCN
5 embryo MP:0005380 9.97 DHX30 FOXG1 GNB1 KIF7 NALCN SLC2A1
6 nervous system MP:0003631 9.86 ADGRG1 DHX30 FOXG1 GALC GNB1 KIF7
7 skeleton MP:0005390 9.28 FOXG1 GALC GNB1 KIF7 STXBP1 TMCO1

Drugs & Therapeutics for Strabismus

Drugs for Strabismus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 160, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Desflurane Approved Phase 4 57041-67-5 42113
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Rimexolone Approved Phase 4 49697-38-3 39507
10
Iodine Approved, Investigational Phase 4 7553-56-2 807
11
Povidone-iodine Approved Phase 4 25655-41-8
12
Povidone Approved Phase 4 9003-39-8
13
Brinzolamide Approved Phase 4 138890-62-7 68844
14
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
17 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
leucovorin Approved Phase 4 58-05-9 6006 143
20
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
21
rituximab Approved Phase 4 174722-31-7 10201696
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
24 Adrenergic alpha-Agonists Phase 4
25 Excitatory Amino Acid Antagonists Phase 4
26 Anesthetics, Dissociative Phase 4
27 Anesthetics, General Phase 4
28 Adrenergic Agents Phase 4
29 Analgesics, Non-Narcotic Phase 4
30 Hypnotics and Sedatives Phase 4
31 Adrenergic Agonists Phase 4
32 Anesthetics, Intravenous Phase 4
33 Ophthalmic Solutions Phase 4
34 Anti-Anxiety Agents Phase 4
35 Psychotropic Drugs Phase 4
36 GABA Modulators Phase 4
37 Anesthetics, Inhalation Phase 4
38 Anti-Allergic Agents Phase 4
39 Norgestimate, ethinyl estradiol drug combination Phase 4
40 Anti-Infective Agents, Local Phase 4
41 cadexomer iodine Phase 4
42 Carbonic Anhydrase Inhibitors Phase 4
43 Gastrointestinal Agents Phase 4
44 Hormones Phase 4
45 Antineoplastic Agents, Hormonal Phase 4
46 Antiemetics Phase 4
47 Hormone Antagonists Phase 4
48 Dermatologic Agents Phase 4
49 glucocorticoids Phase 4
50 Anti-Inflammatory Agents Phase 4
51 Methylprednisolone Acetate Phase 4
52 Neuroprotective Agents Phase 4
53 Protective Agents Phase 4
54 Vitamin B Complex Phase 4
55 Folate Phase 4
56 Vitamin B9 Phase 4
57 Immunoglobulins Phase 4
58 Antibodies Phase 4
59 Folic Acid Antagonists Phase 4
60 Immunoglobulins, Intravenous Phase 4
61 Immunosuppressive Agents Phase 4
62 Immunologic Factors Phase 4
63 Antirheumatic Agents Phase 4
64 Antimetabolites Phase 4
65 Antineoplastic Agents, Immunological Phase 4
66
Atropine Approved, Vet_approved Phase 3 51-55-8, 5908-99-6 174174
67
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
68
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
69
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
70
Racepinephrine Approved Phase 2, Phase 3 329-65-7 838
71
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
72
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
73
Palonosetron Approved, Investigational Phase 3 135729-56-5, 119904-90-4 148211
74 Anesthetics Phase 3
75 Respiratory System Agents Phase 3
76 Anti-Arrhythmia Agents Phase 3
77 Cholinergic Antagonists Phase 3
78 Parasympatholytics Phase 3
79 Anti-Asthmatic Agents Phase 3
80 Muscarinic Antagonists Phase 3
81 Bronchodilator Agents Phase 3
82 Mydriatics Phase 3
83 incobotulinumtoxinA Phase 3
84 abobotulinumtoxinA Phase 3
85 Cholinergic Agents Phase 3
86 Botulinum Toxins Phase 3
87 Botulinum Toxins, Type A Phase 3
88 Neurotransmitter Agents Phase 3
89 Pharmaceutical Solutions Phase 3
90 Anesthetics, Local Phase 2, Phase 3
91 Epinephryl borate Phase 2, Phase 3
92 Serotonin 5-HT3 Receptor Antagonists Phase 3
93
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
94
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
95
Thiopental Approved, Vet_approved Phase 2 76-75-5 3000715
96
Propranolol Approved, Investigational Phase 1, Phase 2 525-66-6 4946
97
Nalbuphine Approved Phase 2 20594-83-6 5311304 5360630
98 Autoantibodies Phase 1, Phase 2
99 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
100 Anticonvulsants Phase 2
101 Trace Elements Phase 2
102 Vitamins Phase 2
103 Nutrients Phase 2
104 Micronutrients Phase 2
105 Adrenergic beta-Antagonists Phase 1, Phase 2
106 Mitogens Phase 1, Phase 2
107 Antihypertensive Agents Phase 1, Phase 2
108 Adrenergic Antagonists Phase 1, Phase 2
109 Endothelial Growth Factors Phase 1, Phase 2
110 Vasodilator Agents Phase 1, Phase 2
111 Analgesics Phase 2
112 Narcotics Phase 2
113
Loteprednol Approved, Experimental 129260-79-3, 82034-46-6 9865442 444025
114
Gabapentin Approved, Investigational 60142-96-3 3446
115 Strawberry Approved
116
Hydromorphone Approved, Illicit 466-99-9 5284570
117
Granisetron Approved, Investigational 109889-09-0 3510
118
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
119
Remifentanil Approved 132875-61-7 60815
120
Lidocaine Approved, Vet_approved 137-58-6 3676
121
Ondansetron Approved 99614-02-5 4595
122
Propofol Approved, Investigational, Vet_approved 2078-54-8 4943
123
Sevoflurane Approved, Vet_approved 28523-86-6 5206
124
Methamphetamine Approved, Illicit 537-46-2 10836
125
Dopamine Approved 51-61-6, 62-31-7 681
126
Histamine Approved, Investigational 51-45-6 774
127
Hydroxyzine Approved 68-88-2 3658
128
Dipivefrin Approved 52365-63-6 3105
129
Droperidol Approved, Vet_approved 548-73-2 3168
130
Calcium carbonate Approved, Investigational 471-34-1
131
Cocaine Approved, Illicit 50-36-2 446220 5760
132
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
133
Methadone Approved 76-99-3 4095
134 Proxymetacaine
135 Anti-Bacterial Agents
136 Antibiotics, Antitubercular
137 Sodium Channel Blockers
138 Diuretics, Potassium Sparing
139 Calamus
140
protease inhibitors
141 HIV Protease Inhibitors
142 Antipsychotic Agents
143 BB 1101
144 Plasma Substitutes
145 Anti-Infective Agents
146 Blood Substitutes
147 Curare
148 Dopamine Agents
149 Sympathomimetics
150 Histamine H1 Antagonists
151 Histamine Antagonists
152
Histamine Phosphate 51-74-1 65513
153 Fibrin Tissue Adhesive
154 Hemostatics
155 Coagulants
156 Dopamine Antagonists
157 Platelet Aggregation Inhibitors
158 Antitussive Agents
159 Chlorpheniramine, phenylpropanolamine drug combination
160 Analgesics, Opioid

Interventional clinical trials:

(showing 182, show less)
# Name Status NCT ID Phase Drugs
1 Intra Ocular Pressure After I-gel and Supreme Insertion Unknown status NCT02508181 Phase 4
2 Clinical Study on the Effects of Propofol for Treatment on Emergence Agitation After Sevoflurane Anesthesia in Pediatric Strabismus Surgery Unknown status NCT02738814 Phase 4 propofol
3 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Unknown status NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
4 The Impact of Botulinum Toxin Injection in the Frontalis on Brow Height and Morphology: A Randomized Trial Unknown status NCT03186001 Phase 4 Abobotulinum toxin A
5 Intranasal Dexmedetomidine Versus Intranasal Midazolam-ketamine Combination for Premedication of Pediatric Patients Undergoing Strabismus Surgery Completed NCT02072083 Phase 4 Dexmedetomidine;Ketamine
6 Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery Completed NCT01901588 Phase 4 Dexmedetomidine
7 The Effect of Anaesthesia Depth on Oculo-cardiac Reflex in Strabismus Surgery Completed NCT02379546 Phase 4 Desflurane
8 The Effect of Penehyclidine on Postoperative Nausea and Vomiting After Strabismus Surgery Completed NCT04054479 Phase 4 Penehyclidine;normal saline
9 Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery (Topical Rimexolone Versus Topical Dexamethasone and Topical Fluorometholone) Completed NCT02816905 Phase 4 0.1 % Dexamethasone;0.1% Fluorometholone;1% Rimexolone
10 Prospective, Randomized, Double-blind Comparison of 5 % Against 1.25 % Povidone-iodine Solution as Preoperative Antisepsis for Strabismus Surgery in Young Children Completed NCT00461656 Phase 4 Preoperative conjunctival irrigation with 5% or 1.25% PI
11 Surgery Associated to Intraoperative Botulinum Toxin A for Large Angle Horizontal Strabismus: a Pilot Study Completed NCT01460355 Phase 4 Botulinum Toxin Type A;saline solution
12 The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia. Completed NCT03349515 Phase 4 Provodine-Iodine Solution;Group B will receive three drops in each eye of ophthalmic balanced salt solution.
13 Dexmedetomidine Versus Midazolam Premedication on Emergence Agitation After Strabismus Surgery in Children Completed NCT01895023 Phase 4 Dexmedetomidine;Midazolam;Saline
14 Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome Completed NCT01312402 Phase 4 topical brinzolamide 1% in 5mL ophthalmic medication;Placebo in 5 mL dispenser
15 Measuring the Functional Effects of Botox on the Brain Using MR Spectroscopy and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
16 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
17 The Effect of Slanted Recession of Horizontal Muscle on Horizontal Strabismus With Abnormal Accommodative Convergence /Accommodation Ratio (AC/A) Unknown status NCT03555045 Phase 2, Phase 3
18 Vision In Preschoolers Study (VIP Study) Unknown status NCT00038753 Phase 3
19 Comparison of Efficacy of 250 Units Versus 500 Units of Botulinum Toxin in the Treatment of Refractory Vaginismus Unknown status NCT00638066 Phase 3 botulinum toxin;botulinum toxin A
20 A Trial of Bifocals in Myopic Children With Esophoria Unknown status NCT00000128 Phase 3
21 A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus Completed NCT01584843 Phase 3 GSK1358820
22 The Prism Adaptation Study (PAS) Completed NCT00000121 Phase 3
23 Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study Completed NCT00785135 Phase 3
24 Effect of Intravenous Fluid Therapy on Postoperative Vomiting in Children Undergoing Otorhinolaryngological Surgery Completed NCT01575600 Phase 3